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Table 2
Cases with refractory to initial treatment
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9 Case 10 Case 11
HC Grade 3 3 3 3 1 2 3 1 3 2 3
Infection Factor BK virus BK+JC virus BK virus BK virus BK+ CMV CMV BK virus BK virus BK virus BK virus BK virus
Onset of HC Treatment Late Late Late Late Late Early Late Early Late Late Late
Hydration + + + + + + + + + + +
Cidofovir + + + + - - + - - + +
Ribavirin - + + + - - - - - - -
Ganciclovir + + - - - - -
Constant Bladder - - + - + - +
Irrigation + + + +
Hematoma - - - - - - +
Discharge - + + +
Selective
embolization of - - - - - - -
vesical artery - - - +
Overall Response no no yes no yes yes no yes no yes yes
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cidofovir (ribavirin), respectively. The treatment has failed
in 3 of 9 patients and all of them have died due to accom-
panying infections. One patient also underwent selective
embolisation of vesical artery (Table 2).
As a result, early-onset HC is related to Cy, but late-onset HC
is usually associated with BK or CMV infections. HC is
generally well treated with i.v hydration and bladder irri-
gation. In some cases antiviral drugs could be needed. Also,
resistant cases may be observed and mortality may be seen
due to HC. It is important that the team, who perform allo-
HSCT, should be prepared for morbidity due to HC and
multidisciplinary treatment algorithm should be designed
which includes cooperation with urology and interventional
radiology clinics.291
Methodological Issues in Exercise Intervention Studies:
Attrition and Adherence
Eileen Danaher Hacker, Maral Mjukian. Biobehavioral Health
Science, University of Illinois at Chicago, Chicago, IL
Purpose: While the beneﬁts of exercise interventions in
people undergoing HCT have been systematically reviewed
elsewhere, subject attrition rates and adherence to exercise
interventions following HCT have not. This systematic review
of the literature examined subject attrition rates and reasons
for attrition as well as adherence to exercise interventions
following BMT/HCT.
Methods: Publications were identiﬁed through literature
searches of PubMed, CINAHL, and Embase as well as hand
searching the references of retrieved studies. Studies pub-
lished between January 1985 and July 2013 that prospec-
tively tested an exercise intervention in BMT/HCT patients
were included. All retrieved abstracts were initially classiﬁed
as (1) exercise intervention studies; (2) studies related to
exercise and/or BMTor HCT that did not prospectively test an
exercise intervention; (3) integrative or systematic reviews
of exercise intervention studies in BMT or HCT patients; or,
(4) other types of reviews articles (i.e., clinical reviews, case
reports, etc.). Studies that prospectively tested an exercise
intervention were further evaluated to determine (1) the
type of exercise modality employed; (2) subject attrition
rates and reasons for attrition; (3) the amount of supervision
required to implement the intervention; (4) timing of the
intervention; and, (5) exercise adherence rates.
Results: Twenty studies met the inclusion criteria. The ma-
jority of studies tested an aerobic exercise intervention (n¼7;35%) or a combination of aerobic and strength training (n¼7;
35%). The aerobic exercise interventions varied and included
activities such as stationary bicycling, walking, or treadmill
walking. Other exercise modalities tested included: (1)
strength training (n¼4; 20%) or (2) combination of stretch-
ing, aerobic and strength training (n¼2; 10%). Supervised
exercise sessions (55%; n ¼ 11) were more commonly used
than unsupervised sessions (20%; n¼ 4). Five studies (25%)
used a combination approach by supervising some sessions
with study participants completing other sessions unsuper-
vised. The overall attrition rate was 18% (180/998 subjects).
Major reasons for attrition included death, change in health
status, protocol issues, personal issues, and lost to follow-up/
no reason provided. Supervised exercise programs rarely
published exercise adherence information. Unsupervised
exercise program relied mainly on self-report to document
adherence. Adherence rates in these studies ranged from 50-
100%.
Conclusion: Questions regarding subject attrition and
adherence to exercise interventions must be addressed to
identify those interventions that are likely to be successful
when translated into clinical practice. Subject attrition from
exercise studies following BMT/HCT is relatively low.
Adherence information for exercise interventions needs to
be regularly addressed.292
Differential Effect of Supersaturated Calcium Phosphate
Rinse and Palifermin on Oral Mucositis Induced By
Conditioning with Fludarabine, Busulfan and TBI or
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Tarik Hadid, Entezam A. Sahovic, Gina Berteotti, John Lister.
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Introduction: Oral mucositis (OM) is a common, debilitating
complication of conditioning regimens for hematopoietic
stem cell transplantation (HSCT). Supersaturated calcium
phosphate rinse (SCPR) and palifermin have shown efﬁcacy
in preventing OM. However, whether their efﬁcacy differs is
unknown. We compared the efﬁcacy of SCPR and palifermin
in HSCT patients receiving myeloablative conditioning.
Methods: A comprehensive review of our institutional
database was performed to identify patients who received
myeloablative-conditioning between 2008 and 2012. Two
cohorts were identiﬁed and analyzed separately. All patients
in the ﬁrst cohort received 400 cGy of total body irradiation
and the majority received Fludarabine 250 mg/m2 and
Prophylactic
Antibiotic
Conventional
Antibiotics
P
value
Total Number of Patients 36 37
Autologous 10 14
Allogeneic Cord Blood 10 9
Allogeneic Bone Marrow 16 14
Positive Blood Cultures 28 29
Gram Positive Total (#Patients) 24 (7) 27 (10)
Gram Negative Total (#Patients) 5 (1) 2 (2)
Mean Discharge Day 43.29 34.74 0.13
Autologous 23.40 18.73 0.99
Allogeneic Cord Blood 62.50 52.80 0.27
Allogeneic Bone Marrow 43.20 35 0.80
Days of Fever 8.71 11.31 0.28
Autologous 7.89 6.46 0.70
Allogeneic 9.72 14.32 0.14
PICU Admission 7 3
Need for Pressors 3 3
Clostridium difﬁcile Diarrhea 6 4
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received melphalan 200 mg/m2. The incidence and grade of
OM were assessed in both groups using the WHO grading
system.
Results: A total of 247 consecutive patients were identiﬁed.
In the FBT cohort, 26 patients received SCPR and 122 pa-
tients received palifermin for OM prophylaxis. In the
Melphalan cohort, 68 patients received SCPR and 31 pa-
tients received palifermin for OM prophylaxis. In the FBT
cohort, the incidence of grade 3 or 4 OM was signiﬁcantly
lower in the palifermin compared to SCPR group (57% vs
100%, OR¼0.19, p<0.0001). The overall incidence of OMwas
lower in the palifermin compared to SCPR group (86% vs
100%, OR¼0.42, p¼0.06). In the melphalan cohort, the
incidence of grade 3 or 4 OM was signiﬁcantly lower in the
SCPR compared to the palifermin group (12% vs 35%,
OR¼0.24, p¼0.008). The overall incidence of OM was lower
in the SCPR compared to the palifermin group (28% vs 58%,
OR¼0.28, p¼0.005).
Conclusion: While palifermin is more effective than SCPR in
preventing FBT-induced OM, SCPR appears more effective in
preventingmelphalan-induced OM. These ﬁndings challenge
the current accepted biological model that views OM as a
universal outcome regardless of the causative agent. We
propose individualized selection of OM prophylactic agent
based on the type of conditioning therapy.293
Prophylactic Broad Spectrum Antibiotics at the Onset of
Neutropenia in HSCT Do Not Change the Number of
Febrile Days or Duration of Hospitalization
Hilary Haines. Pediatrics, Division of Pediatric Hematology/
Oncology, University of Alabama Birmingham, Birmingham, AL
There is increased interest in the use of broad spectrum an-
tibiotics at the onset of neutropenia during hematopoietic
stem cell transplant to prevent serious bacterial infections. In
2009, our group instituted the use of cefepime starting when
the ANC decreased to < 500 as one quality improvement
measure to help reduce the number of serious bacterial in-
fections. This is a preliminary analysis on the efﬁcacy of this
intervention.
All patients undergoing a hematopoietic stem cell trans-
plant from January 2008 to December 2011 were included in
this retrospective analysis. Assignment of patients to each
group was based on intent to treat with 36 patients to have
broad spectrum antibiotic initiated at the onset of neu-
tropenia or with fevers (prophylactic antibiotic group) and
37 patients had antibiotics initiated only for febrile episodes
(conventional antibiotic group). There was no difference
between the two groups in days post transplant for
discharge and number of days of fever. There was a trend
towards a decreased number of febrile days in allogeneic
patients only although this was not statistically signiﬁcant.
8 patients in the prophylactic antibiotic group and 11 pa-
tients conventional antibiotic group had positive blood
culture results at some point during their immediate post-
transplant courses, the majority of which were gram posi-
tive infections. There were 3 deaths prior to hospital
discharge in the conventional antibiotic group, one of sepsis
secondary to vancomycin resistant enterococcus and the
remaining 2 died of respiratory failure due to pulmonary
hemorrhage. There was one death of pulmonary hemor-
rhage associated with refractory GVHD in the prophylactic
antibiotic group.
Despite the fact that there was a decrease in the number of
patients with bacterial infections, preliminary data from thispatient population does not yet indicate an overwhelming
improvement in patient outcomes following the use of pro-
phylactic cefepime at the onset of neutropenia, perhaps due
to the relative infrequency of gram negative bacterial in-
fections. Additional information in a larger number of pa-
tients, including patterns of antibiotic resistance and
duration of antibiotics, may help to deﬁne whether prophy-
lactic antibiotics initiated at the onset of neutropenia change
outcomes.294
Signiﬁcant Transplant-Related Mortality from
Respiratory Virus Infections within the First 100 Days
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Respiratory virus infections are recognized as an important
complication in hematopoietic stem cell transplantation
(HSCT). Respiratory syncytial virus (RSV), inﬂuenza, and
parainﬂuenza have been associated with high morbidity and
mortality post HSCT. Despite an increasing number of re-
ports, knowledge regarding risk factors and long term pul-
monary complications are still very limited. Therefore, we
report our study to evaluate incidence and outcome of res-
piratory virus infections following HSCT in a large pediatric
transplant centre.
Eight hundred and forty four children received HSCT during
the study period (January 2000 and August 2012). The
number of patients undergoing allogeneic (allo) transplant
was 489 and autologous (auto) was 355. Thirty-ﬁve patients
(4.2%) were found to have respiratory virus infection diag-
nosed by a nasopharyngeal aspirate (NPA) in the ﬁrst
100 days post HSCT. Among these, 22 (63%) and 13 (37%)
were allo and auto HSCT recipients, respectively. Upper and
lower respiratory tract infection were documented in 19
(54.3%) and 16 (45.7%) patients, respectively. The viruses
identiﬁed were parainﬂuenza 37%, inﬂuenza 26%, RSV 23%,
adenovirus 11%, and human metapneumovirus 3%. None of
the patients had signiﬁcant respiratory symptoms prior to
HSCT.
